 |
|
|
| |
Fatty Liver, NASH in HIV
|
| |
| |
NATAP Fatty Liver Section http://www.natap.org/liver.htm
Cenicriviroc for HIV, inflammation, fatty liver & NASH Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/08/17)
Cenicriviroc is the fourth CCR-5 inhibitor to make it into later stage clinical development. Only one, maraviroc, completed clinical development and has modest use in clinical practice in the US and in Europe. Cenicriviroc is a clear once daily CCR-5 receptor antagonist with a 30+ hour half-life and activity in early phase clinical trial comparable to the other CCR-5 inhibitors. What makes cenicriviroc more interesting than the potential to be a second in class agent is the fact that this agent also inhibits binding of MCP-1 (monocyte chemoattratant protein one) to the CCR-2 receptor. CCR-2 is expressed on monocytes/macrophage and binding with its ligands, such as MCP-1, results in activation of this cell type. MCP-1 in expressed on endothelial cells, stromal cells and other inflammatory cells and the receptor ligand interaction can lead to increased inflammation in the setting of tissue injury and this interaction may be a mediator of inflammatory diseases including atherosclerosis (8). Even at this meeting an association between monocyte activation and coronary artery calcium was observed in HIV-1 infected individuals (13, 14). Monocyte/macrophage activation and resultant inflammation may be an important component of the inflammatory state in untreated and treated HIV-1 infection and an antiretroviral that may also impact ongoing inflammation has a particular attraction. http://www.natap.org/liver.htm
CROI: FATTY LIVER DISEASE: A GROWING CONCERN - - (04/12/17) a plenary talk by noted fatty liver expert Rohit Loomba from UCSD, Higher prevalence in HIV+ vs general population by 30-40%
"Significant fibrosis and hepatic steatosis are highly prevalent among HIV mono infected patients.At baseline 41% of the patients had significant steatosis (CAP > 238 dB/m) vs. 54% of the patients after 24 months (p = 0.023)
CROI: Changes in Liver Fibrosis and Steatosis in HIV Mono-Infected patients over 24 months - 50% have fatty liver at average age of 46 - (03/28/17)
CROI: LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS - 64% with steatosis among those who had elevated LFTs and/or metabolic syndrome and/or lipodystrophy - (03/28/17) Of 140 patients eligible for liver biopsy, the procedure was performed in 50 (35%). Histological analysis was available for 49 patients and found NAFLD in 76% and NASH in 47%.
EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
|
| |
|
|
|
|
|
